This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.
Be willing and able to sign the informed consent and comply with study procedures.
Be at least 18 years of age.
Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.
Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.
They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.
They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.
They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
They are prisoners, institutionalized individuals, or are unable to consent for themselves.